The conversation around obesity has shifted decisively from the bathroom scale to the scanner table. While body mass index (BMI) remains a screening shorthand, the medical and device industries are now laser-focused on a single, dangerous metric: visceral fat—the hormonally active adipose tissue wrapped around the liver, pancreas, and intestines. Unlike subcutaneous fat, visceral fat is independently linked to insulin resistance, cardiovascular events, and systemic inflammation. In the past six months, a wave of regulatory clearances, clinical trial readouts, and product launches has made visceral fat quantification not just a research tool, but a mainstream consumer health metric. This report examines the latest industry movements, the emerging trend of combining GLP-1 receptor agonists with bioimpedance monitoring, and the strategic shift toward imaging-based metabolic phenotyping.

Wearables Move Beneath the Skin: Bioimpedance Goes Segmental

The most significant industry development in Q3 2025 is the commercialization of segmental bioelectrical impedance analysis (BIA) in consumer wearables. Historically, BIA devices measured whole-body impedance, offering only a crude estimate of total fat. That limitation is now obsolete. In July, a major consumer electronics manufacturer received FDA Class II clearance for a smartwatch featuring a multi-frequency, 6-electrode array embedded in the wristband and a secondary contact ring on the opposite hand. The device generates a localized impedance map across the trunk, specifically isolating the android (abdominal) region. Early validation studies, presented at the American Diabetes Association’s 85th Scientific Sessions, demonstrated a correlation coefficient of 0.87 against dual-energy X-ray absorptiometry (DXA) for visceral adipose tissue (VAT) area—a dramatic improvement over previous whole-body estimates.

Industry analysts note that this is not merely an incremental hardware update. The shift from “fat percentage” to “visceral fat grade” (measured in cm² of VAT area) changes the user’s behavioral trigger. A consumer who sees a VAT area of 180 cm² is more likely to initiate a medical consultation than one who sees a 28% body fat reading. Several telehealth providers have already integrated these wearable outputs into their weight-management protocols, allowing physicians to remotely track VAT changes on a weekly basis. However, critics within the clinical community caution that BIA remains hydration-sensitive and may overestimate VAT in athletes or underestimate it in patients with edema. The industry response has been to pair BIA with photoplethysmography (PPG) and heart-rate variability data, creating a composite “metabolic stress score” that contextualizes the impedance reading.

The GLP-1 Coadministration Trend: Monitoring as a Companion to Pharmacotherapy

The second major trend is the deliberate pairing of visceral fat monitoring with GLP-1 receptor agonist therapy. As semaglutide and tirzepatide prescriptions have surged, a growing body of evidence suggests that these drugs reduce visceral fat disproportionately to subcutaneous fat—but the degree of reduction varies widely between individuals. In a recent post-hoc analysis of a 72-week Phase 3 trial, researchers found that participants in the highest tertile of baseline VAT (measured by CT) lost 23% of their visceral fat versus 11% in the lowest tertile, despite identical weight loss. This heterogeneity has created a clinical need for real-time monitoring.

In response, at least two digital therapeutics companies have launched “coadministration programs” that bundle a GLP-1 prescription with a subscription-based BIA wearable and a clinician dashboard. The dashboard generates a “VAT response curve” that predicts whether a patient is a “fast responder” (VAT loss >15% by week 12) or a “non-responder” who might benefit from a dose adjustment or alternative therapy. Early pilot data from a 400-patient cohort in Germany showed that patients using the combined approach achieved a 31% higher VAT reduction at week 24 compared to those on GLP-1 monotherapy without monitoring, primarily due to earlier dose titration. Regulatory bodies have taken note: the European Medicines Agency’s Committee for Medicinal Products for Human Use recently issued a draft reflection paper on “digital companion endpoints” for metabolic drugs, signaling that VAT area may become a secondary efficacy endpoint in future label claims.

Imaging-Based Metabolic Phenotyping: The New Clinical Gold Standard

While wearables capture the consumer market, the clinical sector is moving toward advanced imaging to resolve the limitations of BIA. The most notable development is the expansion of low-dose CT-based “body composition screening” as an add-on to routine abdominal scans. In May, a leading radiology network in the United States announced that all non-contrast abdominal CTs performed at its 120 centers would now automatically include an AI-driven VAT and subcutaneous fat segmentation report. Using a convolutional neural network trained on 40,000 annotated scans, the software generates a VAT area, a VAT-to-subcutaneous ratio, and a liver attenuation value (a proxy for hepatic steatosis) within 90 seconds. The clinical rationale is simple: many patients undergoing CT for unrelated complaints (e.g., kidney stones, appendicitis) have undiagnosed metabolic syndrome. The incidental finding of a VAT area >160 cm² now triggers a referral pathway to an endocrinologist.

This trend is not confined to the United States. In Japan, the Ministry of Health has proposed a national screening program for adults aged 40–70 using a single-slice CT at the L4-L5 vertebral level, a method validated by the Japan Society for the Study of Obesity. The program’s cost-effectiveness analysis, published inThe Lancet Regional Health – Western Pacific, suggests that identifying high-VAT individuals early and intervening with lifestyle modification could reduce the 10-year incidence of type 2 diabetes by 18%. Parallel efforts in Europe are exploring magnetic resonance imaging (MRI) proton-density fat fraction (PDFF) as a radiation-free alternative, though the higher cost and longer scan times currently limit it to tertiary care settings.

Expert Viewpoints: A Shift from Weight-Centric to Adipose-Centric Medicine

Industry observers and clinicians are increasingly aligning on a unified message: visceral fat is the modifiable risk factor that matters most. Dr. Elena Vasquez, a metabolic physician at the Karolinska Institute and a key opinion leader in obesity medicine, commented in a recent industry webinar: “We have spent two decades treating the number on the scale. That number is a poor proxy for cardiometabolic risk. A patient can have a normal BMI and a dangerously high VAT area—the so-called ‘TOFI’ phenotype (thin outside, fat inside). Conversely, a muscular individual may have a high BMI but a healthy VAT. The industry’s move toward direct VAT measurement, whether through BIA or imaging, is the single most important correction to the obesity paradigm since the discovery of adipokines.”

Dr. Marcus Chen, a cardiologist and digital health advisor to a major wearable manufacturer, added a cautionary note on data interpretation: “The technology is advancing faster than the clinical guidelines. We do not yet have a universally agreed-upon VAT threshold that dictates when to start pharmacological intervention. The 160 cm² cutoff used in many studies is population-derived, not individualized. I urge my colleagues to use VAT trends rather than absolute values for clinical decisions, and to always consider the patient’s age, sex, and ethnicity—Asian populations, for instance, develop metabolic complications at lower VAT areas than Caucasians.”

Market Dynamics and Forward Outlook

The commercial implications are substantial. The global visceral fat measurement market, encompassing BIA devices, CT/MRI software, and AI analytics, is projected to grow from $1.4 billion in 2024 to $3.9 billion by 2030, according to a recent industry report. This growth is fueled not only by consumer demand but by payer interest. Several private insurers in the U.S. have begun reimbursing for “metabolic health coaching” that includes weekly VAT tracking, citing the potential to reduce long-term costs associated with cardiovascular disease and bariatric surgery.

However, unresolved challenges remain. Standardization across BIA devices is inconsistent, with some manufacturers using proprietary algorithms that produce VAT values not directly comparable to others. The imaging community has yet to agree on a single AI model for VAT segmentation, leading to potential variability in clinical trials. Moreover, the psychological impact of real-time VAT feedback is understudied—early data suggests that some patients may experience “adipose anxiety,” leading to overly restrictive eating behaviors.

Looking ahead, the next 18 months will likely see the integration of continuous glucose monitors (CGMs) with VAT wearables, creating a closed-loop feedback system where dietary choices are immediately reflected in both glucose excursions and VAT estimates. Additionally, the first phase of a large-scale randomized trial testing whether VAT-guided lifestyle intervention reduces cardiovascular events (the “VAT-HEART” trial) is expected to complete enrollment by mid-2026. If positive, this trial could crystallize visceral fat as a primary therapeutic target, not just a biomarker.

The industry narrative is clear: the era of generalized obesity management is ending, replaced by a precise, spatially aware understanding of where fat resides—and how to remove the most dangerous portion of it. As the tools for measurement become cheaper, more accurate, and more integrated into daily life, the conversation between patient and physician will no longer begin with “how much do you weigh?” but rather, “what is your visceral fat area, and what are we going to do about it?”